
MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial
A novel cholesterol-lowering drug may offer a new approach to reducing cardiovascular risk in patients with elevated triglycerides and remnant cholesterol, beyond the reach of traditional therapies.1 In late-breaking data announced by Marea Therapeutics on …